LANADELUMAB

BRAND NAME	TAKHZYRO
DRUG CLASS	Monoclonal antibody (human) for hereditary angioedema (HAE)
AVAILABILITY	Prefilled syringe contains 300 mg/2 mL of lanadelumab. Also contains dibasic sodium phosphate dihydrate, cirtic acid monohydrate, histidine, sodium chloride and polysorbate-80.[1] Contain 3.4 5mg (0.15 mmol) of sodium.[1] The solution is clear to slightly opalescent and colourless to slightly yellow.[1]
pH	6.0[1]
PREPARATION	Ready to use. Allow the syringe to reach room temperature.[2] **Do not shake**.[1]
STABILITY	Store at 2 to 8 °C. Do not freeze. Protect from light.[1] Stable for 14 days below 25 °C. Do not return to the fridge.[1]
ADMINISTRATION	
IM injection	Not recommended
SUBCUT injection	Inject into the abdomen, thigh or upper arm. Rotate the site of injection.[1] The first dose must be given under medical supervision. Subsequent doses may be suitable for self-administration after appropriate training.[1]
IV injection	Not recommended
IV infusion	Not recommended
COMPATIBILITY	No information
INCOMPATIBILITY	No information
SPECIAL NOTES	Injection site reactions are usually mild to moderate and include pain, flushing, redness, itching and rash.[1]

REFERENCES
1. Product information. Available from www.tga.gov.au. Accessed 24/03/2022.
2. Consumer medicine information. Available from www.tga.gov.au. Accessed 24/03/2022.